What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Mark J. Ratain mainly focuses on Pharmacology, Internal medicine, Pharmacokinetics, Toxicity and Gastroenterology.
His Pharmacology research includes elements of Irinotecan, Glucuronidation and Pharmacogenetics.
His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology, Surgery and Oncology.
Within one scientific family, he focuses on topics pertaining to Glucuronide under Pharmacokinetics, and may sometimes address concerns connected to Diarrhea.
His studies in Toxicity integrate themes in fields like Immunology and Chemotherapy.
His research integrates issues of Recombinant DNA, Renal function, Hairy cell leukemia, Leukemia and Bone marrow in his study of Gastroenterology.
His most cited work include:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (3607 citations)
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (939 citations)
- Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. (828 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Pharmacology, Pharmacokinetics, Oncology and Toxicity.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery.
He has researched Pharmacology in several fields, including Irinotecan and Pharmacogenetics.
He combines subjects such as Pharmacogenomics and Bioinformatics with his study of Pharmacogenetics.
The concepts of his Pharmacokinetics study are interwoven with issues in Metabolite, Endocrinology and Glucuronide.
His Oncology study integrates concerns from other disciplines, such as Bevacizumab, Colorectal cancer, Genome-wide association study and Breast cancer.
He most often published in these fields:
- Internal medicine (38.24%)
- Pharmacology (38.51%)
- Pharmacokinetics (23.66%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (38.24%)
- Oncology (20.22%)
- Pharmacogenomics (7.57%)
In recent papers he was focusing on the following fields of study:
Mark J. Ratain spends much of his time researching Internal medicine, Oncology, Pharmacogenomics, Pharmacology and Pharmacogenetics.
His research combines Gastroenterology and Internal medicine.
His Oncology research incorporates elements of Cetuximab, Clinical trial, Proportional hazards model, Bevacizumab and Single-nucleotide polymorphism.
His research on Pharmacogenomics also deals with topics like
- MEDLINE and related Medical prescription,
- Family medicine that connect with fields like Genomic information.
His study in Pharmacokinetics and Pharmacodynamics are all subfields of Pharmacology.
In his study, Genetic association and Drug response is inextricably linked to Genome-wide association study, which falls within the broad field of Pharmacogenetics.
Between 2015 and 2021, his most popular works were:
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. (219 citations)
- Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). (163 citations)
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. (110 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Mark J. Ratain focuses on Internal medicine, Pharmacogenomics, Pharmacology, Clinical trial and Pharmacogenetics.
Mark J. Ratain interconnects Gastroenterology and Oncology in the investigation of issues within Internal medicine.
The Pharmacology study combines topics in areas such as Clinical endpoint and Intensive care medicine.
His research in Clinical trial intersects with topics in Interquartile range, Medical physics and Response Evaluation Criteria in Solid Tumors.
His Pharmacogenetics research incorporates themes from Guideline, Drug, Genome-wide association study and Bioinformatics.
His research investigates the connection with Genome-wide association study and areas like Genetic association which intersect with concerns in Toxicity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
